Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at ESMO Virtual Congress 2020
Stock Information for Oncternal Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.